Questcor Pharmaceuticals Inc. (QCOR): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Questcor Pharmaceuticals ( QCOR) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.1%. By the end of trading, Questcor Pharmaceuticals rose 82 cents (3.4%) to $24.96 on light volume. Throughout the day, 1.9 million shares of Questcor Pharmaceuticals exchanged hands as compared to its average daily volume of 5.6 million shares. The stock ranged in a price between $24.14-$25.50 after having opened the day at $24.31 as compared to the previous trading day's close of $24.14. Other companies within the Health Care sector that increased today were: Novogen ( NVGN), up 74.6%, MEI Pharma ( MEIP), up 61.4%, Graymark Healthcare ( GRMH), up 25%, and Rosetta Genomics ( ROSG), up 17.3%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides prescription drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. Questcor Pharmaceuticals has a market cap of $1.39 billion and is part of the drugs industry. The company has a P/E ratio of 9.2, below the S&P 500 P/E ratio of 17.7. Shares are down 42.8% year to date as of the close of trading on Monday. Currently there are seven analysts that rate Questcor Pharmaceuticals a buy, no analysts rate it a sell, and three rate it a hold.

TheStreet Ratings rates Questcor Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year.

On the negative front, Vivus ( VVUS), down 20.9%, Anthera Pharmaceuticals ( ANTH), down 19.7%, Cambrex Corporation ( CBM), down 16.3%, and Oxygen Biotherapeutics ( OXBT), down 12.7%, were all laggards within the health care sector with Medivation ( MDVN) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.
null

If you liked this article you might like

Cramer: Reviewing S&P's Hit-and-Miss Parade

Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015

Greenberg on the Stock Market: Why Investigations No Longer Matter

Retrophin CEO Under Fire for Twitter Faux Pas

Questcor Pharmaceuticals (QCOR) Hits New Lifetime High Today